ARTICLE | Politics, Policy & Law
AstraZeneca may defer U.S. cancer drug launches in response to IRA
Price-setting provisions of IRA could lead AZ, other companies to make decisions that hurt patients
November 11, 2022 1:18 AM UTC
AstraZeneca said the Inflation Reduction Act is leading it to consider dramatic changes to its R&D and commercialization strategies, including some that would harm patients in the U.S. by delaying access to new drugs.
On an earnings call Thursday, senior executives at AstraZeneca plc (LSE:AZN; NASDAQ:AZN) said the company may defer U.S. launches of some cancer drugs to maximize revenues before the IRA’s price-setting provisions come into effect. They also signaled their intention to deprioritize development of small molecules and other drugs regulated under the NDA pathway...
Get Unlimited Access
To view this item, login or register for a free account.
Or Purchase This Article